Posted

Bridge to Life Reintroduces EasiSlush® to the US Market, Meeting High Demand for Easy-to-Use Sterile Slush for Organ Transplantation

Bridge to Life Ltd, a leading provider of organ preservation solutions, today announces the return of EasiSlush™ to the US market, effective immediately. With its unmatched ease of use, high [...]

Posted

Bridge to Life Achieves ISO 13485:2016 Certification, Reinforcing Commitment to Quality and Safety in Hypothermic Oxygenated Perfusion and Cold Flush Organ Preservation Solutions

Bridge to Life Ltd, a renowned market leader in cold flush organ preservation solutions, is proud to announce its recent certification for ISO 13485:2016. This achievement further solidifies the [...]

Posted

Bridge to Life Statement on KSE Recall

Earlier this week Bridge to Life (BTL) became aware of the distribution of a recall notice from Krackeler Southeast Scientific LLC (KSE which was acquired by ILC Dover) to OPO’s. BTL wanted to [...]

Posted

Bridge to Life Divests Certain Assets to TransMedics

Bridge to Life Ltd. announced today its divestiture of certain assets to TransMedics, Inc., a wholly owned subsidiary of TransMedics Group, Inc., including its EVOSS heart and lung and LifeCradle [...]

Posted

ADVANCING TRANSPLANTATION TECHNOLOGIES: Bridge to HOPE Trial Demonstrates Promising Findings with Hypothermic Oxygenated Perfusion

Bridge to Life Ltd. announced results from interim analysis of its multicenter, randomized, controlled liver clinical trial presented at the 2023 American Transplant Congress (ATC).

Posted

Early Closure of Bridge to Life Ltd. HOPE Liver Trial Enrollment Affirms the Potential of Hypothermic Oxygenated Perfusion

Bridge to Life, Ltd. announced that it met positive criteria from interim analysis for early enrollment closure of its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

page 1 of 2